Immuneering (IMRX) financial statements
Net income was -$56M.
Free cash flow was -$45M.
The diluted share count rose 789% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Immuneering's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | $316,952 | $0 | — | — |
| Cost of revenue | $1M | $1M | $158,122 | $0 | — | — |
| Gross profit | $1M | $926,888 | $158,830 | $0 | — | — |
| Research and development | $15M | $27M | $36M | $42M | $48M | $42M |
| Selling, general and admin | $3M | $8M | $16M | $17M | $16M | $17M |
| Operating income | -$17M | -$34M | -$52M | -$58M | -$64M | -$59M |
| Pre-tax income | -$17M | -$34M | -$51M | — | — | — |
| Income tax | — | -$307,485 | — | — | — | $0 |
| Net income | -$17M | -$34M | -$51M | -$53M | -$61M | -$56M |
| EPS (diluted) | -$3.44 | -$2.46 | -$1.91 | -$1.88 | -$2.04 | -$1.27 |
| Diluted shares | 5M | 14M | 26M | 28M | 30M | 44M |
| Gross margin | 44.6% | 44.6% | 50.1% | — | — | — |
| Operating margin | -739.0% | -1629.2% | -16325.8% | — | — | — |
| Net margin | -737.2% | -1612.3% | -15937.3% | — | — | — |
Balance sheet
Fiscal years, from Immuneering's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $37M | $149M | $106M | $86M | $36M | $129M |
| Receivables | $500,110 | $246,040 | $12,417 | $0 | — | — |
| Total current assets | $38M | $152M | $109M | $89M | $40M | $176M |
| Property, plant and equipment | $64,363 | $807,223 | $1M | $1M | $1M | $938,481 |
| Goodwill | — | $7M | $7M | $7M | $7M | $7M |
| Total assets | $38M | $167M | $122M | $103M | $53M | $232M |
| Total current liabilities | $2M | $6M | $8M | $8M | $8M | $10M |
| Total liabilities | $3M | $11M | $13M | $12M | $11M | $14M |
| Shareholders' equity | -$22M | $156M | $110M | $91M | $41M | $218M |
| Net debt | -$37M | -$75M | -$73M | -$59M | -$36M | -$129M |
Cash flow
Fiscal years, from Immuneering's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | -$31M | -$44M | -$49M | -$55M | -$45M |
| Capital spending | $53,415 | $60,786 | $742,483 | $342,746 | $84,875 | $142,226 |
| Free cash flow | -$15M | -$31M | -$45M | -$49M | -$55M | -$45M |
| Stock-based compensation | $1M | $2M | $4M | $6M | $7M | $6M |
| Free cash flow margin | -634.8% | -1486.2% | -14148.4% | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMRX.
Open IMRX in InvestinglyQuestions
How much free cash flow does Immuneering generate?
-$45M in fiscal 2025 (operating cash flow minus capital spending).
From Immuneering's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.